Zobrazeno 1 - 10
of 786
pro vyhledávání: ''
Autor:
Daniela Bohr, K. Manger, Bernhard Manger, Georg Schett, Verena Schoenau, Thomas Harrer, Gerhard Krönke, Arnd Kleyer, David Simon, Koray Tascilar, Filippo Fagni, Johannes Knitza, Katja Schmidt, Andreas Ramming
Publikováno v:
Annal of the Rheumatic Diseases
ObjectivesTotestwhether patients with immune-mediated inflammatory disease (IMIDs), who did not respond to two doses of the SARS-CoV-2 vaccine, develop protective immunity, if a third vaccine dose is administered.MethodsPatients with IMID who failed
Autor:
J Garg, Analia Alvarez, Elizabeth Zuta-Santillan, Paul Brunetta, Ana Malvar, Cary M. Looney, Brad H. Rovin, Thomas Schindler, Richard Furie, Matthew D Cascino, Imran Hassan, Gustavo Aroca, Hilda Fragoso-Loyo
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveRandomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II anti-CD20 monoclonal antibody that induces potent B-cell d
Autor:
Anja Strangfeld, Ana M. Rodrigues, Loreto Carmona, Ludovic Trefond, Charalampos Papagoras, Laure Gossec, N Roux, Kimme L. Hyrich, Saskia Lawson-Tovey, Bernd Raffeiner, Elsa F Mateus, Gözde Kübra Yardımcı, Pedro Machado, Xavier Mariette
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Lawson-Tovey, S, Hyrich, K L, Gossec, L, Strangfeld, A, Carmona, L, Raffeiner, B, Yardımcı, G K, Trefond, L, Roux, N, Rodrigues, A, Papagoras, C, Mateus, E F, Mariette, X & Machado, P M 2021, ' SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2021-221217
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Annals of the Rheumatic Diseases, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Lawson-Tovey, S, Hyrich, K L, Gossec, L, Strangfeld, A, Carmona, L, Raffeiner, B, Yardımcı, G K, Trefond, L, Roux, N, Rodrigues, A, Papagoras, C, Mateus, E F, Mariette, X & Machado, P M 2021, ' SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases ', Annals of the rheumatic diseases . https://doi.org/10.1136/annrheumdis-2021-221217
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2022, 81 (1), pp.145-150. ⟨10.1136/annrheumdis-2021-221217⟩
Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are often treated with immunomodulatory or immunosuppressive medications; consequently, they have been excluded alongside other immunocompromised patients from late stages of S
Autor:
Michael Bonelli, Stephan Blüml, Philipp Hofer, Leonhard X. Heinz, Stefan Winkler, Daniela Sieghart, Josef S Smolen, Marianne Graninger, Daniel Aletaha, Karin Stiasny, Helmuth Haslacher, Helga Radner, Selma Tobudic, Maximilian Koblischke, Renate Thalhammer, Thomas Perkmann, Daniel Mrak, Judith H. Aberle
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesEvidence suggests that B cell-depleting therapy with rituximab (RTX) affects humoral immune response after vaccination. It remains unclear whether RTX-treated patients can develop a humoral and T-cell-mediated immune response against SARS-C
Publikováno v:
Annals of the Rheumatic Diseases. 80:1393-1399
BackgroundHepatitis B surface antigen (HBsAg) reverse seroconversion (RS) can happen in patients with rheumatoid arthritis (RA) with resolved hepatitis B (RHB) undergoing biological disease-modifying antirheumatic drugs (bDMARDs). But the incidence a
Autor:
Julien H Djossou, Pierre-Marie Duret, Elodie Bauer, Jean Hugues Salmon, Jean Sibilia, Francis Berenbaum, Isabelle Chary-Valckenaere, Jérémy Fort, M. Geoffroy, Christelle Sordet, Alain Meyer, Emmanuel Chatelus, Cassandre Fabre, Massiva Bensalem, J. Walther, Laurent Messer, Renaud Felten, Martin Soubrier, Laurent Arnaud, Luc Pijnenburg, Marion Couderc, Jacques-Eric Gottenberg, Nicolas Meyer, Jérémie Sellam, Rose-Marie Javier, Nathanael Sedmak, A. Fan, Marina Rinagel, M. Ardizzone
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2021, ⟨10.1136/annrheumdis-2021-220549⟩
Annals of the Rheumatic Diseases, 2021, ⟨10.1136/annrheumdis-2021-220549⟩
Dear Editor, A potential association between rituximab and more severe COVID-19 outcomes has been previously raised, based on case reports, retrospective studies and mostly declarative registries.1–4 To further investigate this association, we focu
Autor:
Caoilfhionn M Connolly, Teresa Po-Yu Chiang, Lisa Christopher-Stine, Allan B. Massie, Jennifer L. Alejo, Mayan Teles, William A. Werbel, Brian J. Boyarsky, Ami A. Shah, Julie J. Paik, Dorry L. Segev, Jacqueline Garonzik-Wang, Jake A Ruddy
Publikováno v:
Annals of the Rheumatic Diseases. 81:293-295
Mycophenolate is the mainstay of treatment for many organ and life-threatening manifestations of rheumatic and musculoskeletal diseases (RMD). In contrast to most patients with RMD, those taking mycophenolate have an attenuated humoral response to SA
Autor:
Zachary S. Wallace, Alessandra Zaccardelli, Michael A. DiIorio, Naomi J Patel, Lauren C. Prisco, Kristin M. D’Silva, Derrick J. Todd, Claire Cook, Kathleen M M Vanni, Lily W Martin, Jeffrey A. Sparks, Tiffany Hsu
Publikováno v:
Ann Rheum Dis
SARS-CoV-2 vaccines reduce the risk of COVID-19.1–3 However, some disease-modifying anti-rheumatic drugs (DMARDs), particularly glucocorticoids, methotrexate, mycophenolate mofetil and rituximab, may blunt the immunological response to COVID-19 vac
Autor:
Jialin Teng, Hui Shi, Zhuochao Zhou, Ce Shi, Fan Wang, Yue Sun, Yijun You, Xiaobing Cheng, Junna Ye, Chengde Yang, Yutong Su, Honglei Liu
Publikováno v:
Annals of the Rheumatic Diseases. 80:820-822
Antiphospholipid syndrome (APS) is a multisystem disorder defined by a combination of arterial and/or venous thrombosis, recurrent fetal loss in women and persistent presence of antiphospholipid (aPL) antibodies such as lupus anticoagulant (LAC), ant
Autor:
Andreas Kronbichler, Markus Stein, Erica L Bettac, Manfred Nairz, Barbara C. Böckle, Philipp Gauckler, Peter Schratzberger, David Wanner, Martin Tiefenthaler, Gert Mayer, Hannes Neuwirt, Lukas Harasser, Anna Luger, Christina Duftner
Publikováno v:
Annals of the Rheumatic Diseases
Antineutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV) are characterised by a heterogeneous clinical phenotype.1 We report a cluster of 15 patients diagnosed with AAV either de novo (n=11) or with relapsing disease (n=4) during COVI